Loading
A phase 3 trial of Atezolizumab, Carboplatin, Etoposide in small-cell lung cancer, run by Boehringer Ingelheim, now recruiting.
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy is a phase 3 interventional study registered as NCT07472517 by Boehringer Ingelheim, with 670 participants planned, started 2026-04-13 and due to reach its primary completion in 2028-09-09. Interventions recorded: obrixtamig, atezolizumab, carboplatin, etoposide. Conditions listed: Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC). No results are recorded here; the registry entry is the source.
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Topoisomerase-I inhibitors (and ADC payloads).
Shares Obrixtamig, Boehringer Ingelheim, Etoposide, Topoisomerase-I inhibitors (and ADC payloads).
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Topoisomerase-I inhibitors (and ADC payloads).
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Topoisomerase-I inhibitors (and ADC payloads).
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Topoisomerase-I inhibitors (and ADC payloads).
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents.
Shares Obrixtamig, Boehringer Ingelheim, Atezolizumab, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents.